硼替佐米-环磷酰胺-地塞米松与利妥昔单抗治疗PGNMID的对比
该单中心、开放标签、预试验随机对照研究纳入20例PGNMID患者,1:1随机接受BCD方案(6周期)或利妥昔单抗(375 mg/m²,每周4次,B细胞重建>5/μL者6个月时追加500 mg)治疗。主要终点12个月总体肾脏缓解率在BCD组为60%(6/10)、RTX组为70%(7/10)(P=1.0)。两组蛋白尿均下降、血清白蛋白改善;BCD组6个月eGFR短暂下降、12个月恢复。结论:两种疗法均与肾脏缓解相关,样本量小、开放标签,结果仅为假说生成。
要点
- BCD与利妥昔单抗在PGNMID中12个月总体肾脏缓解率分别为60%和70%,差异无统计学意义(P=1.0)。
- BCD组6个月eGFR短暂下降、12个月恢复;安全性总体可控,BCD组发生1例肺炎严重不良事件。
- 结果因样本量小(n=20)、开放标签设计而仅为探索性,需更大规模多中心研究验证。
核心结论
- 在PGNMID探索性预试验中,BCD方案与利妥昔单抗均与12个月肾脏缓解相关(60% vs 70%,P=1.0)。
- 因样本量小、开放标签及治疗暴露结构差异,结果仅为假说生成,需更大规模多中心研究确定最佳疗法。
研究设计与样本
- 单中心、开放标签、预试验随机对照研究,纳入20例PGNMID患者,1:1随机分组。
- BCD组接受6周期BCD方案;RTX组接受利妥昔单抗375 mg/m²每周4次,B细胞重建>5/μL者6个月时追加500 mg。
- 主要疗效终点为12个月总体肾脏缓解;次要终点包括6和12个月蛋白尿、血清白蛋白及eGFR变化;安全性包括感染和血液学毒性。
主要发现
- 意向性分析(n=20)12个月总体肾脏缓解率BCD组60%(6/10)、RTX组70%(7/10),P=1.0。
- 治疗失败BCD组2例、RTX组0例;6个月完全缓解BCD组5例、RTX组3例。
- 两组12个月内蛋白尿均下降、血清白蛋白均改善;BCD组6个月eGFR短暂下降、12个月恢复。
- BCD组发生1例肺炎严重不良事件,安全性总体可控。
- 基线中位年龄57岁,平均蛋白尿4.1 ± 3.1 g/d,两组基线特征基本均衡。
关键数值与推荐
- 纳入20例PGNMID患者,随机1:1接受BCD(6周期)或利妥昔单抗375 mg/m²每周4次。
- B细胞重建>5/μL者6个月时接受利妥昔单抗500 mg追加剂量。
- 主要终点12个月总体肾脏缓解率:BCD组60%(6/10)vs RTX组70%(7/10),P=1.0。
临床怎么用
- BCD与利妥昔单抗均可作为PGNMID的克隆导向治疗选择,但现有证据仅为探索性。
- BCD治疗期间需关注6个月eGFR短暂下降及感染风险(如肺炎)。
- 治疗决策应个体化,并优先考虑纳入更大规模临床试验。
局限性
- 样本量小(n=20),统计效能有限。
- 开放标签设计可能引入偏倚。
- 两组治疗暴露结构不同(BCD 6周期 vs 利妥昔单抗4周+可选追加),影响直接比较。
- 随访时间仅12个月,长期疗效与安全性未知。
- 单中心研究,结果外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare renal disorder for which prospective controlled treatment evidence is limited. Clone-directed therapies targeting plasma cells or B cells are increasingly used, but comparative prospective data are lacking. METHODS: This single-center, open-label, pilot RCT aimed to evaluate the feasibility and preliminary efficacy of plasma cell-targeted therapy (bortezomib-cyclophosphamide-dexamethasone, BCD) versus B-cell-targeted therapy (rituximab, RTX). Twenty eligible patients were randomized (1:1) to receive either 6 cycles of BCD or 4 weekly doses of rituximab at375 mg/m². In patients with B-cell reconstitution > 5/μL, a 500 mg rituximab booster dose was administered at 6 months according to the prespecified protocol. The primary efficacy endpoint was overall renal response at 12 months. Changes in proteinuria, serum albumin and estimated glomerular filtration rate were also assessed at 6 and 12 months as secondary outcomes. Safety outcomes included infections and hematologic toxicity. RESULTS: Baseline characteristics were generally comparable between groups. The median age was 57 years, and mean proteinuria 4.1 ± 3.1 g/d. In the primary intention-to-treat analysis (n = 20), the primary outcome of overall renal response at 12 months was observed in 60% (6/10) of patients in the BCD group and 70% (7/10) in the RTX group (P = 1.0). Treatment failure occurred in 2 patients in the BCD group and none in the RTX group. At 6 months, complete response occurred in five patients in the BCD group and three patients in the RTX group. Both groups showed reductions in proteinuria and improvements in serum albumin over 12 months. A transient decline in estimated glomerular filtration rate was observed in the BCD group at 6 months and recovered by 12 months. Safety profiles were manageable, with one serious adverse event, pneumonia, in the BCD group. CONCLUSION: Both BCD and rituximab were associated with renal responses in this exploratory pilot trial of PGNMID. Given the small sample size, open-label design, and differences in treatment exposure structure, these findings are hypothesis-generating. Larger multicenter studies with longer follow-up are needed to define optimal therapy for PGNMID.Trial registration: chictr.org.cn Identifier: ChiCTR2500102928.
引用
- Zhang X, Yu XJ, Wang Z, et al. Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID. Nephrol Dial Transplant. 2026. PMID: 42343619. doi:10.1093/ndt/gfag146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。